New treatment modalities with vaccine therapy in renal cell carcinoma

Area of Science:

• Urology
• Immunology
• Oncology

Background:

• Vaccine therapy aims to stimulate an immune response against malignant cells by overcoming tumor-induced tolerance.
• Not all cancers are suitable for vaccine therapies; they require immunogenic properties, slow progression, and feasible treatment protocols.
• Urological cancer research, particularly for renal cell carcinoma (RCC), is increasingly focusing on vaccine-based immunotherapies.

Purpose of the Study:

• To review current vaccine therapies for renal cell carcinoma (RCC).
• To discuss the potential of these therapies in managing RCC, especially in metastatic settings.
• To increase urologists' familiarity with advanced RCC vaccine treatments.

Main Methods:

• Review of existing literature on vaccine therapies for RCC.
• Categorization of RCC vaccine approaches: autologous tumor cells, dendritic cells, genetically modified tumor cells, and protein/peptide-based vaccines.
• Analysis of recent research trends and clinical outcomes.

Main Results:

• Vaccine therapies show potential in lengthening overall survival and reducing tumor burden in RCC patients.
• These treatments are particularly effective in patients with metastatic RCC.
• Recent research has intensified, indicating a growing interest and development in RCC vaccine therapies.

Conclusions:

• Renal cell carcinoma (RCC) is immunogenic, making it a suitable candidate for vaccine therapies.
• Vaccine treatments offer a promising avenue for improving long-term outcomes and managing metastatic RCC.
• Increased application of vaccine therapies in clinical practice is anticipated due to their effectiveness and ongoing research.